{"id":"NCT04217590","sponsor":"AstraZeneca","briefTitle":"Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects","officialTitle":"A Phase 3b, Multicentre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-16","primaryCompletion":"2022-01-03","completion":"2022-01-03","firstPosted":"2020-01-03","resultsPosted":"2023-03-28","lastUpdate":"2023-03-28"},"enrollment":134,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperkalemia"],"interventions":[{"type":"DRUG","name":"Sodium Zirconium Cyclosilicate","otherNames":["SZC; Lokelma; ZS"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sodium Zirconium Cyclosilicate (SZC)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of Sodium Zirconium Cyclosilicate (SZC), as well as the appropriateness of the dosing mechanism, in Chinese end-stage renal disease (ESRD) patients on chronic haemodialysis.","primaryOutcome":{"measure":"Percentage of Responders","timeFrame":"Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.","effectByArm":[{"arm":"Sodium Zirconium Cyclosilicate (SZC)","deltaMin":25,"sd":null},{"arm":"Placebo","deltaMin":7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":36,"countries":["China"]},"refs":{"pmids":["37385905","32588430"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D9485C00001&amp;attachmentIdentifier=1c10b684-b39c-4155-a455-25f3ec2a77c2&amp;fileName=CSP_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D9485C00001&amp;attachmentIdentifier=5e2a8f35-b41e-4685-899a-6ffa81781403&amp;fileName=Statistical_Analysis_Plan_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D9485C00001&amp;attachmentIdentifier=8fff0273-c810-405f-9ee1-2145eff8f169&amp;fileName=CSR_synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":66},"commonTop":["Hypokalaemia","Constipation","Dialysis hypotension","Hypotension","Upper respiratory tract infection"]}}